{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:49:33Z","timestamp":1793339373318,"version":"4.5.0"},"reference-count":193,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.phrs.2025.107918","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:49:35Z","timestamp":1755650975000},"page":"107918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-3850","authenticated-orcid":false,"given":"Florian","family":"Freudenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Reif-Leonhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard R.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth M.","family":"McKernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.phrs.2025.107918_bib1","first-page":"1","article-title":"Major depressive disorder","volume":"1","author":"Marx","year":"2023","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2025.107918_bib2","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.107918_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"20","key":"10.1016\/j.phrs.2025.107918_bib4","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/mp.2015.92","article-title":"Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder","volume":"10","author":"Papakostas","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib5","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-024-01875-z","article-title":"Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression","author":"Freudenberg","year":"2024","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.neubiorev.2015.03.005","article-title":"The role of \u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity","volume":"52","author":"Freudenberg","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.phrs.2025.107918_bib7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib8","first-page":"8272","article-title":"History and evolution of the monoamine hypothesis of depression","volume":"61","author":"Hirschfeld","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib9","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2174\/138161209788168001","article-title":"Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today","volume":"15","author":"Lopez-Munoz","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2025.107918_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","article-title":"Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments","volume":"102","author":"Duman","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2025.107918_bib11","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.biopsych.2012.11.009","article-title":"The action of antidepressants on the glutamate system: regulation of glutamate release and glutamate receptors","volume":"73","author":"Musazzi","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41380-018-0252-9","article-title":"Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies","volume":"24","author":"Moriguchi","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.pbb.2011.04.016","article-title":"Roles of glutamate signaling in preclinical and\/or mechanistic models of depression","volume":"100","author":"Tokita","year":"2011","journal-title":"Pharm. Biochem. Behav."},{"key":"10.1016\/j.phrs.2025.107918_bib14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.biopsych.2010.06.016","article-title":"Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders","volume":"68","author":"Y\u00fcksel","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108922","article-title":"Glutamate receptors and synaptic plasticity: the impact of evans and watkins","volume":"206","author":"Collingridge","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.31887\/DCNS.2008.10.4\/gracagni","article-title":"Cellular and molecular mechanisms in the long-term action of antidepressants","volume":"10","author":"Racagni","year":"2008","journal-title":"Dialog. Clin. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S2215-0366(17)30015-9","article-title":"How do antidepressants work? New perspectives for refining future treatment approaches","volume":"4","author":"Harmer","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.npp.1301574","article-title":"Stress, depression, and neuroplasticity: a convergence of mechanisms","volume":"33","author":"Pittenger","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","author":"Duman","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2025.107918_bib20","article-title":"Structural neural plasticity evoked by rapid-acting antidepressant interventions","author":"Liao","year":"2024","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/1570159X14666160202121111","article-title":"Synaptic plasticity, metaplasticity and depression","volume":"15","author":"Vose","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41583-021-00540-x","article-title":"The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders","volume":"23","author":"Sanacora","year":"2022","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib23","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neuron.2020.06.002","article-title":"The bidirectional relationship of depression and inflammation: double trouble","volume":"107","author":"Beurel","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2025.107918_bib24","article-title":"Inflammation effects on brain glutamate in depression: mechanistic considerations and treatment implications, curr top","volume":"31","author":"Haroon","year":"2017","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/ejn.14720","article-title":"Neuroinflammation and depression: a review","volume":"53","author":"Troubat","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib26","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41380-023-02397-1","article-title":"Targeting metaplasticity mechanisms to promote sustained antidepressant actions","author":"Brown","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-J","article-title":"Functional antagonists at the NMDA receptor complex exhibit antidepressant actions","volume":"185","author":"Trullas","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib28","unstructured":"P. Skolnick, Antidepressants for the new millennium, 1999. \u3008www.elsevier.nlrlocaterejphar\u3009."},{"key":"10.1016\/j.phrs.2025.107918_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2007-979537","article-title":"Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression","volume":"29","author":"Skolnick","year":"1996","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib31","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib32","first-page":"114","article-title":"Long-term study of fluvoxamine: a new rapid-acting antidepressant","volume":"17","author":"Feldmann","year":"1982","journal-title":"Int. Pharmacopysch."},{"key":"10.1016\/j.phrs.2025.107918_bib33","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1021\/jm00170a031","article-title":"4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. a novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants","volume":"33","author":"Sarges","year":"1990","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.107918_bib34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0014-2999(87)90523-1","article-title":"Potential antidepressant properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin1A receptor agonist","volume":"144","author":"Cervo","year":"1987","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib35","first-page":"37","article-title":"Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: the neurotransmitter receptor hypothesis of antidepressant action","volume":"45","author":"Stahl","year":"1984","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib36","first-page":"121","article-title":"Experience with a new rapid-acting antidepressant: amoxapine","volume":"32","author":"Cancro","year":"1982","journal-title":"Adv. Biochem Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/bs.apha.2019.03.002","article-title":"Rapid-acting antidepressants","volume":"86","author":"Witkin","year":"2019","journal-title":"Adv. Pharm."},{"key":"10.1016\/j.phrs.2025.107918_bib38","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/15622975.2024.2441304","article-title":"Effects of repeated intravenous esketamine administration on affective biases","volume":"26","author":"Reif-Leonhard","year":"2025","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib39","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1113\/jphysiol.2014.273763","article-title":"Molecular bases of NMDA receptor subtype-dependent properties","volume":"593","author":"Glasgow","year":"2015","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2025.107918_bib40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn3504","article-title":"NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease","volume":"14","author":"Paoletti","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib41","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.neubiorev.2017.08.012","article-title":"Molecular and cellular dissection of NMDA receptor subtypes as antidepressant targets","volume":"84","author":"Lang","year":"2018","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.phrs.2025.107918_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cophys.2017.12.004","article-title":"Triheteromeric NMDA receptors: from structure to synaptic physiology","volume":"2","author":"Stroebel","year":"2018","journal-title":"Curr. Opin. Physiol."},{"key":"10.1016\/j.phrs.2025.107918_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108609","article-title":"NMDA receptor function in inhibitory neurons","volume":"196","author":"Booker","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev-med-051322-120608","article-title":"Ketamine: mechanisms and relevance to treatment of depression","volume":"75","author":"Kim","year":"2024","journal-title":"Annu Rev. Med."},{"key":"10.1016\/j.phrs.2025.107918_bib46","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.abb6748","article-title":"Enhanced ERK activity extends ketamine\u2019s antidepressant effects by augmenting synaptic plasticity","volume":"388","author":"Ma","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.107918_bib47","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib48","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/ijnp\/pyab045","article-title":"Opioid properties of nitrous oxide and ketamine contribute to their antidepressant actions","volume":"24","author":"Gillman","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib49","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","article-title":"Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents","volume":"117","author":"Klein","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107918_bib50","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/14740338.2022.2047928","article-title":"Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"21","author":"Bahji","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.phrs.2025.107918_bib51","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.phrs.2025.107918_bib52","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jpsychires.2024.11.010","article-title":"Intranasal esketamine for patients with major depressive disorder: a systematic review and meta-analysis","volume":"180","author":"Oraee","year":"2024","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.phrs.2025.107918_bib53","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1176\/appi.ajp.20240515","article-title":"Esketamine treatment for depression in adults: a PRISMA systematic review and Meta-Analysis","volume":"182","author":"Fountoulakis","year":"2025","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib54","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107918_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.01.016","article-title":"Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders","volume":"159","author":"Nguyen","year":"2016","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.phrs.2025.107918_bib56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14728214.2021.1898588","article-title":"Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials","volume":"26","author":"Majeed","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.phrs.2025.107918_bib57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ajad.12389","article-title":"Recreational use of dextromethorphan, \u201cRobotripping\u201d\u2014A brief review","volume":"25","author":"Stanciu","year":"2016","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.phrs.2025.107918_bib58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbr.2015.03.024","article-title":"Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice","volume":"295","author":"Nguyen","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.phrs.2025.107918_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089985","article-title":"Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan","volume":"9","author":"Nguyen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2025.107918_bib60","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1176\/appi.ajp.21080800","article-title":"Effect of AXS-05 (Dextromethorphan-Bupropion) in major depressive disorder: a randomized Double-Blind controlled trial","volume":"179","author":"Tabuteau","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib61","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14345","article-title":"Efficacy and safety of AXS-05 (Dextromethorphan-Bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI","volume":"83","author":"Iosifescu","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib62","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.1992.tb04134.x","article-title":"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes","volume":"34","author":"Crewe","year":"1992","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.116257","article-title":"Early augmentation therapy with dextromethorphan in mild to moderate major depressive disorder: a group sequential, response adaptive randomized controlled trial","volume":"342","author":"Maji","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.phrs.2025.107918_bib64","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.mehy.2012.02.012","article-title":"An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan","volume":"78","author":"Lauterbach","year":"2012","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.phrs.2025.107918_bib65","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.biopha.2016.11.073","article-title":"The role of NMDA receptor and nitric oxide\/cyclic guanosine monophosphate pathway in the antidepressant-like effect of dextromethorphan in mice forced swimming test and tail suspension test","volume":"85","author":"Sakhaee","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2025.107918_bib66","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/WNR.0000000000000646","article-title":"Behavioral and biochemical effects of ketamine and dextromethorphan relative to its antidepressant-like effects in Swiss webster mice","volume":"27","author":"Nguyen","year":"2016","journal-title":"Neuroreport"},{"key":"10.1016\/j.phrs.2025.107918_bib67","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.expneurol.2007.06.013","article-title":"A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder","volume":"207","author":"Werling","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.phrs.2025.107918_bib68","doi-asserted-by":"crossref","DOI":"10.1186\/s40345-019-0174-8","article-title":"Combination of dextromethorphan and memantine in treating bipolar spectrum disorder: a 12-week double-blind randomized clinical trial","volume":"8","author":"Lee","year":"2020","journal-title":"Int J. Bipolar Disord."},{"key":"10.1016\/j.phrs.2025.107918_bib69","unstructured":"Otsuka Holdings Company Limited, Consolidated Financial Results for the Fiscal Year Ended December 31, 2016, 2017. \u3008https:\/\/ssl4.eir-parts.net\/doc\/4578\/ir_material_for_fiscal_ym2\/101965\/00.pdf\u3009 (accessed April 20, 2025)."},{"key":"10.1016\/j.phrs.2025.107918_bib70","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pbb.2017.09.005","article-title":"Deuterated (d6)-dextromethorphan elicits antidepressant-like effects in mice","volume":"161","author":"Nguyen","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.phrs.2025.107918_bib71","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1213\/01.ane.0000205751.88422.41","article-title":"Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat","volume":"102","author":"Lemberg","year":"2006","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.phrs.2025.107918_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15055-3","article-title":"REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in sprague dawley rats","volume":"12","author":"Henningfield","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2025.107918_bib73","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JCP.0000000000001035","article-title":"Characterization of the safety and pharmacokinetic profile of d -Methadone, a novel n -Methyl- d -Aspartate receptor antagonist in healthy, Opioid-Naive subjects: results of two phase 1 studies","volume":"39","author":"Bernstein","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib74","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00406-023-01571-4","article-title":"Esmethadone-HCl (REL-1017): a promising rapid antidepressant","volume":"273","author":"Fava","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1176\/appi.ajp.2021.21020197","article-title":"REL-1017 (Esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized Double-Blind trial","volume":"179","author":"Fava","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib76","unstructured":"Relmada Therapeutics, Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017, 2024. \u3008https:\/\/www.relmada.com\/for-investors\/news\/detail\/307\/relmada-therapeutics-to-discontinue-the-reliance-ii-and\u3009 (accessed April 10, 2025)."},{"key":"10.1016\/j.phrs.2025.107918_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.671859","article-title":"REL-1017 (Esmethadone) increases circulating BDNF levels in healthy subjects of a phase 1 clinical study","volume":"12","author":"De Martin","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib78","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/s41386-019-0501-x","article-title":"N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects","volume":"44","author":"Foga\u00e7a","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib79","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2468-2667(24)00298-6","article-title":"Tackling the growing burden of nitrous oxide-induced public health harms","volume":"10","author":"Zaloum","year":"2025","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.phrs.2025.107918_bib80","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/acps.13432","article-title":"Nitrous oxide for the treatment of psychiatric disorders: a systematic review of the clinical trial landscape","volume":"146","author":"Liu","year":"2022","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.phrs.2025.107918_bib81","doi-asserted-by":"crossref","DOI":"10.1007\/s00406-024-01801-3","article-title":"The boon and bane of nitrous oxide","author":"Kronenberg","year":"2024","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib82","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/bmb\/ldx050","article-title":"Past, present, and future of nitrous oxide","volume":"125","author":"Lew","year":"2018","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.phrs.2025.107918_bib83","doi-asserted-by":"crossref","first-page":"9716","DOI":"10.1523\/JNEUROSCI.18-23-09716.1998","article-title":"Effect of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures","volume":"18","author":"Mennerick","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib84","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1590\/1516-4446-2020-1543","article-title":"Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial","volume":"43","author":"Guimar\u00e3es","year":"2021","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib85","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.biopsych.2014.11.016","article-title":"Nitrous oxide for treatment-resistant major depression: a proof-of-concept trial","volume":"78","author":"Nagele","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe1376","article-title":"A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression","volume":"13","author":"Nagele","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2025.107918_bib87","article-title":"Antidepressant effects of nitrous oxide in major depressive disorder: a phase 2b randomized clinical trial","volume":"0","author":"Myles","year":"2025","journal-title":"Biol. Psychiatry Glob. Open Sci."},{"key":"10.1016\/j.phrs.2025.107918_bib88","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1038\/s41467-025-57951-y","article-title":"Nitrous oxide activates layer 5 prefrontal neurons via SK2 channel inhibition for antidepressant effect","volume":"16","author":"Cichon","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107918_bib89","article-title":"Repeated nitrous oxide exposure exerts Antidepressant-Like effects through neuronal nitric oxide synthase activation in the medial prefrontal cortex","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib90","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1007\/s12035-018-1364-6","article-title":"Cortical excitability and activation of TrkB signaling during rebound slow oscillations are critical for rapid antidepressant responses","volume":"56","author":"Kohtala","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2025.107918_bib91","unstructured":"D. Cattano, S. Valleggi, A. Abramo, F. Forfori, M. Maze, F. Giunta, Nitrous Oxide Discretely Up-regulates nNOS and p53 in Neonatal Rat Brain, 2010."},{"key":"10.1016\/j.phrs.2025.107918_bib92","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ijnp\/pyy101","article-title":"Positive N-Methyl-D-Aspartate receptor modulation by rapastinel promotes rapid and sustained Antidepressant-Like effects","volume":"22","author":"Donello","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172827","article-title":"Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: convergent mechanisms","volume":"188","author":"Kato","year":"2020","journal-title":"Pharm. Biochem. Behav."},{"key":"10.1016\/j.phrs.2025.107918_bib94","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/ph18020157","article-title":"Demystifying the antidepressant mechanism of action of stinels, a novel class of neuroplastogens: positive allosteric modulators of the NMDA receptor","volume":"18","author":"Donello","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.phrs.2025.107918_bib95","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1017\/S1461145712000910","article-title":"A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression","volume":"16","author":"Heresco-Levy","year":"2013","journal-title":"Int J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib96","doi-asserted-by":"crossref","DOI":"10.1186\/s40345-023-00308-5","article-title":"NRX-101 (D-cycloserine plus lurasidone) vs. Lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial","volume":"11","author":"Nierenberg","year":"2023","journal-title":"Int. J. Bipolar Disord."},{"key":"10.1016\/j.phrs.2025.107918_bib97","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/ijnp\/pyac043","article-title":"Zelquistinel is an orally bioavailable novel NMDA receptor allosteric modulator that exhibits rapid and sustained Antidepressant-Like effects","volume":"25","author":"Burgdorf","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib98","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41386-020-00882-7","article-title":"Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons","volume":"46","author":"Pothula","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib99","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuropharm.2016.09.011","article-title":"Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures","volume":"111","author":"Lepack","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib100","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/mp.2017.220","article-title":"BDNF release and signaling are required for the antidepressant actions of GLYX-13","volume":"23","author":"Kato","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib101","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/npp.2012.246","article-title":"GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects","volume":"38","author":"Burgdorf","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib102","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-022-02290-5","article-title":"ERK\/mTOR signaling May underlying the antidepressant actions of rapastinel in mice","volume":"12","author":"Shen","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib103","first-page":"1","article-title":"PI3K\/AKT\/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13","volume":"18","author":"Lu","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib104","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3233\/JAD-161251","article-title":"A meta-analysis of memantine for depression","volume":"57","author":"Kishi","year":"2017","journal-title":"J. Alzheimer\u2019S. Dis."},{"key":"10.1016\/j.phrs.2025.107918_bib105","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/npp.2016.224","article-title":"Adjunctive lanicemine (AZD6765) in patients with major depressive disorder and history of inadequate response to antidepressants: a randomized, Placebo-Controlled study","volume":"42","author":"Sanacora","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib106","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41386-024-02011-0","volume":"49","author":"McIntyre","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib107","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neuron.2009.02.027","article-title":"Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach","volume":"62","author":"Lu","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2025.107918_bib108","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(01)00321-X","article-title":"Subunit-specific rules governing AMPA receptor trafficking to synapses in hippocampal pyramidal neurons","volume":"105","author":"Shi","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107918_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108708","article-title":"GluA1-homomeric AMPA receptor in synaptic plasticity and neurological diseases","volume":"197","author":"Ge","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40263-018-0492-x","article-title":"Convergent mechanisms underlying rapid antidepressant action","volume":"32","author":"Zanos","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2025.107918_bib111","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s40473-015-0050-5","article-title":"Novel glutamatergic treatments for severe mood disorders","volume":"2","author":"Park","year":"2015","journal-title":"Curr. Behav. Neurosci. Rep."},{"key":"10.1016\/j.phrs.2025.107918_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.860882","article-title":"The mechanisms behind rapid antidepressant effects of ketamine: a systematic review with a focus on molecular neuroplasticity","volume":"13","author":"Kang","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109308","article-title":"Role of the AMPA receptor in antidepressant effects of ketamine and potential of AMPA receptor potentiators as a novel antidepressant","volume":"222","author":"Suzuki","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib114","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107918_bib115","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuropharm.2019.04.019","article-title":"Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine","volume":"153","author":"Shaffer","year":"2019","journal-title":"Neuropharmacology"},{"issue":"7659","key":"10.1016\/j.phrs.2025.107918_bib116","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature22084","article-title":"Effects of a ketamine metabolite on synaptic NMDAR function","volume":"546","author":"Suzuki","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107918_bib117","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.biopsych.2017.10.020","article-title":"Common neurotransmission recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced sustained Antidepressant-like effects","volume":"84","author":"Pham","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib118","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1073\/pnas.1816071116","article-title":"Antidepressant-relevant concentrations of the ketamine metabolite (2 R,6 R)-hydroxynorketamine do not block NMDA receptor function","volume":"116","author":"Lumsden","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107918_bib119","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.3391","article-title":"1 assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of (2R,6R)-Hydroxynorketamine in healthy volunteers","volume":"116","author":"Raja","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2025.107918_bib120","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-020-0663-6","article-title":"Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression","author":"Farmer","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib121","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpsychires.2019.08.005","article-title":"Ketamine metabolite pilot study in a suicidal depression trial","volume":"117","author":"Grunebaum","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.phrs.2025.107918_bib122","doi-asserted-by":"crossref","unstructured":"A.C. Arai, M. Kessler, Pharmacology of Ampakine Modulators: From AMPA Receptors to Synapses and Behavior, 2007.","DOI":"10.2174\/138945007780618490"},{"key":"10.1016\/j.phrs.2025.107918_bib123","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2174\/1381612053764814","article-title":"AMPA receptor potentiators as novel antidepressants","volume":"11","author":"Alt","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2025.107918_bib124","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bcp.2005.12.022","article-title":"A role for AMPA receptors in mood disorders","volume":"71","author":"Alt","year":"2006","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/187152707780363258","article-title":"AMPA receptors in the therapeutic management of depression","volume":"6","author":"Bleakman","year":"2008","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.phrs.2025.107918_bib126","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568007043337508","article-title":"AMPA receptor potentiators for the treatment of CNS disorders","volume":"3","author":"O\u2019Neill","year":"2004","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.phrs.2025.107918_bib127","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.drudis.2021.07.027","article-title":"Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: a long and winding road","volume":"26","author":"Kadriu","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2025.107918_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2025.173967","article-title":"Amplification of the therapeutic potential of AMPA receptor potentiators from the nootropic era to today","volume":"248","author":"Radin","year":"2025","journal-title":"Pharm. Biochem. Behav."},{"key":"10.1016\/j.phrs.2025.107918_bib129","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/13543776.2013.770840","article-title":"AMPA receptor positive allosteric modulators: a patent review","volume":"23","author":"Pirotte","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.phrs.2025.107918_bib130","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1527-3458.2002.tb00228.x","article-title":"LY404187: a novel positive allosteric modulator of AMPA receptors","volume":"8","author":"Quirk","year":"2002","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.phrs.2025.107918_bib131","doi-asserted-by":"crossref","unstructured":"X. Li, J.P. Tizzano, K. Griffey, M. Clay, T. Lindstrom, P. Skolnick, Antidepressant-like Actions of an AMPA Receptor Potentiator (LY392098), 2001. \u3008www.elsevier.com\/locate\/neuropharm\u3009.","DOI":"10.1016\/S0028-3908(00)00194-5"},{"key":"10.1016\/j.phrs.2025.107918_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115924","article-title":"AMPAkine CX516 alleviated chronic ethanol exposure-induced neurodegeneration and depressive-like behavior in mice","volume":"439","author":"Yao","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib133","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1007\/s12035-020-01954-x","article-title":"Antidepressant-Like effects of CX717, a positive allosteric modulator of AMPA receptors","volume":"57","author":"Gordillo-Salas","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2025.107918_bib134","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-2999(02)01338-9","article-title":"Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model","volume":"440","author":"Knapp","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib135","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.biopha.2018.06.008","article-title":"Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain","volume":"105","author":"Radin","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2025.107918_bib136","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00213-008-1325-2","article-title":"Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat","volume":"202","author":"Woolley","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib137","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.neuroscience.2008.12.018","article-title":"Ampakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expression","volume":"159","author":"Lauterborn","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2025.107918_bib138","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1152\/jn.00336.2006","article-title":"Restoration of long-term potentiation in middle-aged hippocampus after induction of brain-derived neurotrophic factor","volume":"96","author":"Rex","year":"2006","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.phrs.2025.107918_bib139","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.neuropharm.2009.01.015","article-title":"BDNF mediates the neuroprotective effects of positive AMPA receptor modulators against MPP+-induced toxicity in cultured hippocampal and mesencephalic slices","volume":"56","author":"Jourdi","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib140","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.phrs.2011.10.004","article-title":"The AMPA receptor potentiator org 26576 modulates stress-induced transcription of BDNF isoforms in rat hippocampus","volume":"65","author":"Fumagalli","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2025.107918_bib141","doi-asserted-by":"crossref","unstructured":"B. Legutko, X. Li, P. Skolnick, Regulation of BDNF Expression in Primary Neuron Culture by LY392098, a Novel AMPA receptor potentiator, 2001. \u3008www.elsevier.com\/locate\/neuropharm\u3009.","DOI":"10.1016\/S0028-3908(01)00006-5"},{"key":"10.1016\/j.phrs.2025.107918_bib142","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1124\/jpet.117.245050","article-title":"HBT1, a novel ampa receptor potentiator with lower agonistic effect, avoided bell-shaped response in in vitro BDNF productions","volume":"364","author":"Kunugi","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2025.107918_bib143","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pbb.2019.06.004","article-title":"TAK-137, an AMPA receptor potentiator with little agonistic effect, produces antidepressant-like effect without causing psychotomimetic effects in rats","volume":"183","author":"Suzuki","year":"2019","journal-title":"Pharm. Biochem. Behav."},{"key":"10.1016\/j.phrs.2025.107918_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173289","article-title":"TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats","volume":"211","author":"Hara","year":"2021","journal-title":"Pharm. Biochem. Behav."},{"issue":"11","key":"10.1016\/j.phrs.2025.107918_bib145","first-page":"1","article-title":"Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement","volume":"1","author":"Suzuki","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2025.107918_bib146","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mp.2017.241","article-title":"Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling","volume":"23","author":"Cavalleri","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib147","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1111\/ejn.12638","article-title":"Prolonged ampakine exposure prunes dendritic spines and increases presynaptic release probability for enhanced long-term potentiation in the hippocampus","volume":"40","author":"Chang","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib148","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.brainresrev.2004.02.003","article-title":"Critical role of brain-derived neurotrophic factor in mood disorders","volume":"45","author":"Hashimoto","year":"2004","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.phrs.2025.107918_bib149","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00213-009-1598-0","article-title":"Chronic treatment with AMPA receptor potentiator org 26576 increases neuronal cell proliferation and survival in adult rodent hippocampus","volume":"206","author":"Su","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib150","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0028-3908(03)00104-7","article-title":"Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus","volume":"44","author":"Bai","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177317","article-title":"Safety, tolerability and pharmacokinetic profile of the low-impact ampakine CX717 in young healthy Male subjects and elderly healthy Male and female subjects","volume":"993","author":"Radin","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib152","article-title":"Safety, tolerability, and pharmacokinetic profile of the Low-Impact ampakine CX1739 in young healthy volunteers","author":"Radin","year":"2024","journal-title":"Clin. Pharm. Drug Dev."},{"key":"10.1016\/j.phrs.2025.107918_bib153","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/11634360-000000000-00000","article-title":"Maximum tolerated dose evaluation of the AMPA modulator org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection","volume":"12","author":"Nations","year":"2012","journal-title":"Drugs R. D."},{"key":"10.1016\/j.phrs.2025.107918_bib154","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1177\/0269881112458728","article-title":"Examination of org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial","volume":"26","author":"Nations","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib155","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/0269881119872198","article-title":"Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profile","volume":"34","author":"Ward","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib156","first-page":"1272","article-title":"Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers","author":"Wezenberg","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib157","unstructured":"Neurocrine Biosciences, Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder SAVITRI TM Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery \u00c5sberg Depression Rating Scale (MADRS) Total Score at Day 28 Met Key Secondary Endpoints, Including Statistically Significant Reduction in MADRS Score at Day 56 NBI-1065845 Was Generally Well-Tolerated, 2024. \u3008https:\/\/www.prnewswire.com\/news-releases\/neurocrine-biosciences-reports-positive-phase-2-data\u3009-."},{"key":"10.1016\/j.phrs.2025.107918_bib158","unstructured":"Servier, Efficacy and safety of S 47445 Versus Placebo as Adjunctive Treatment of Major Depressive Disorder in Patients with an Inadequate Response to Antidepressant therapy. A randomised, double-blind, placebo controlled international, multicentre study. - Servier Clinical Trials, (2018). \u3008https:\/\/clinicaltrials.servier.com\/trial\/efficacy-and-safety-of-s-47445-versus-placebo-as-adjunctive-treatment-of-major-depressive-disorder-in-patients-with-an-inadequate-response-to-antidepressant-therapy-a-randomised-double-blind-placeb\/\u3009 (accessed April 7, 2025)."},{"issue":"76","key":"10.1016\/j.phrs.2025.107918_bib159","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s00018-019-03068-7","article-title":"AMPA receptors and their minions: auxiliary proteins in AMPA receptor trafficking","volume":"11","author":"Bissen","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.phrs.2025.107918_bib160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00441-006-0275-4","article-title":"Role of AMPA receptors in synaptic plasticity","volume":"326","author":"Sprengel","year":"2006","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.phrs.2025.107918_bib161","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bpsgos.2022.02.007","article-title":"Dysfunction of glutamatergic synaptic transmission in depression: focus on AMPA receptor trafficking","volume":"3","author":"He","year":"2022","journal-title":"Biol. Psychiatry Glob. Open Sci."},{"key":"10.1016\/j.phrs.2025.107918_bib162","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1113\/JP276698","article-title":"Modulation of information processing by AMPA receptor auxiliary subunits","volume":"599","author":"Jacobi","year":"2021","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2025.107918_bib163","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1113\/JP278701","article-title":"AMPA receptor structure and auxiliary subunits","volume":"599","author":"Kamalova","year":"2021","journal-title":"J. Physiol."},{"key":"10.1016\/j.phrs.2025.107918_bib164","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.coph.2021.03.011","article-title":"Beyond the AMPA receptor: diverse roles of SynDIG\/PRRT brain-specific transmembrane proteins at excitatory synapses","volume":"58","author":"D\u03afaz","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib165","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrn.2016.18","article-title":"Mechanistic basis of MAGUK-organized complexes in synaptic development and signalling","author":"Zhu","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib166","doi-asserted-by":"crossref","first-page":"19518","DOI":"10.1074\/jbc.273.31.19518","article-title":"SAP97 is associated with the \u03b1-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR1 subunit","volume":"273","author":"Leonard","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107918_bib167","doi-asserted-by":"crossref","first-page":"31484","DOI":"10.1074\/jbc.M204354200","article-title":"Selective binding of synapse-associated protein 97 to GluR-A alpha-amino-5-hydroxy-3-methyl-4-isoxazole propionate receptor subunit is determined by a novel sequence motif","volume":"277","author":"Cai","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107918_bib168","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1471-4159.2006.03831.x","article-title":"Direct interaction of post-synaptic density-95\/Dlg\/ZO-1 domain-containing synaptic molecule Shank3 with GluR1 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor","volume":"97","author":"Uchino","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2025.107918_bib169","article-title":"Exploring the role of AMPA receptor auxiliary proteins in synaptic functions and diseases","author":"Qneibi","year":"2024","journal-title":"FEBS J."},{"key":"10.1016\/j.phrs.2025.107918_bib170","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/nn1551","article-title":"TARP \u03b3-8 controls hippocampal AMPA receptor number, distribution and synaptic plasticity","author":"Rouach","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib171","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0578-24.2025","article-title":"Aniracetam ameliorates attention deficit hyperactivity disorder behavior in adolescent mice","volume":"12","author":"Sun","year":"2025","journal-title":"ENeuro"},{"key":"10.1016\/j.phrs.2025.107918_bib172","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2016.09.002","article-title":"CaMKII phosphorylation of TARP\u03b3-8 is a mediator of LTP and learning and memory","volume":"92","author":"Park","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2025.107918_bib173","doi-asserted-by":"crossref","first-page":"851","DOI":"10.24272\/j.issn.2095-8137.2022.122","article-title":"Deficiency of transmembrane AMPA receptor regulatory protein \u03b3-8 leads to attention-deficit hyperactivity disorder-like behavior in mice","volume":"43","author":"Bai","year":"2022","journal-title":"Zool. Res."},{"key":"10.1016\/j.phrs.2025.107918_bib174","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-42780-8","article-title":"Enhanced TARP-\u03b38-PSD-95 coupling in excitatory neurons contributes to the rapid antidepressant-like action of ketamine in Male mice","volume":"14","author":"Xue","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107918_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102504","article-title":"Gene-environment interactions mediate stress susceptibility and resilience through the CaMKII\u03b2\/TARP\u03b3-8\/AMPAR pathway","volume":"24","author":"Sakai","year":"2021","journal-title":"IScience"},{"key":"10.1016\/j.phrs.2025.107918_bib176","unstructured":"Rapport Therapeutics, Pipeline and Programs, (n.d.). \u3008https:\/\/www.rapportrx.com\/pipeline\/\u3009 (accessed April 28, 2025)."},{"key":"10.1016\/j.phrs.2025.107918_bib177","unstructured":"Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Electronic address: andrew.mcintosh@ed.ac.uk, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies., Cell 188 (2025) 640-652.e9. https:\/\/doi.org\/10.1016\/J.CELL.2024.12.002\/ASSET\/C50942E3-CE73-4D14-A8F5-9D9A99BD689A\/MAIN.ASSETS\/FIGS1.JPG."},{"key":"10.1016\/j.phrs.2025.107918_bib178","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.1038\/s41380-021-01217-8","article-title":"Shisa6 mediates cell-type specific regulation of depression in the nucleus accumbens","volume":"26","author":"Kim","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib179","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.biopsych.2018.03.001","article-title":"Metabotropic glutamate receptor 5 as a target for the treatment of depression and smoking: robust preclinical data but inconclusive clinical efficacy","volume":"83","author":"Barnes","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2019.07.011","article-title":"Enhanced mGlu5 signaling in excitatory neurons promotes rapid antidepressant effects via AMPA receptor activation","volume":"104","author":"Holz","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2025.107918_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107081","article-title":"A molecular perspective on mGluR5 regulation in the antidepressant effect of ketamine","volume":"200","author":"Elmeseiny","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107918_bib182","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00406-023-01561-6","article-title":"mGlu2\/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development","volume":"273","author":"Chaki","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2025.107918_bib183","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12470","article-title":"Randomized, Double-Blind, Placebo-Controlled trial of the mGlu2\/3 negative allosteric modulator decoglurant in partially refractory major depressive disorder","volume":"81","author":"Umbricht","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2025.107918_bib184","unstructured":"Saniona, S.A.N.2465, (n.d.). \u3008https:\/\/saniona.com\/pipeline\/san2465\/\u3009 (accessed April 26, 2025)."},{"key":"10.1016\/j.phrs.2025.107918_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2024.137828","article-title":"Basmisanil, an \u03b15-GABAAR negative allosteric modulator, produces rapid and sustained antidepressant-like responses in Male mice","volume":"833","author":"Daher","year":"2024","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2025.107918_bib186","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.neuropharm.2007.08.008","article-title":"Blockade of alcohol\u2019s amnestic activity in humans by an \u03b15 subtype benzodiazepine receptor inverse agonist","volume":"53","author":"Nutt","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2025.107918_bib187","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1570159X14666160309114549","article-title":"Molecular and cellular mechanisms of Rapid-Acting antidepressants ketamine and scopolamine","volume":"15","author":"Wohleb","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.phrs.2025.107918_bib188","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40263-022-00964-8","article-title":"Clinical effectiveness of muscarinic Receptor-Targeted interventions in neuropsychiatric disorders: a systematic review","author":"Vaidya","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2025.107918_bib189","doi-asserted-by":"crossref","unstructured":"W.-D. Ludwig, B. M\u00fchlbauer Roland Seifert Hrsg, Arzneiverordnungs-Report 2023, Springer Berlin Heidelberg, Berlin, Heidelberg, 2023. https:\/\/doi.org\/10.1007\/978-3-662-68371-2.","DOI":"10.1007\/978-3-662-68371-2"},{"key":"10.1016\/j.phrs.2025.107918_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103518","article-title":"Inflammation, stress and depression: an exploration of ketamine\u2019s therapeutic profile","volume":"28","author":"Johnston","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2025.107918_bib191","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMoa052963","article-title":"Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression","volume":"354","author":"Rush","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107918_bib192","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa052964","article-title":"Medication augmentation after the failure of SSRIs for depression","volume":"354","author":"Trivedi","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107918_bib193","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.euroneuro.2024.12.013","article-title":"Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: findings from a 32-week randomised, open-label, rater-blinded phase IIIb study","volume":"93","author":"Vieta","year":"2025","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825003433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825003433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:13:29Z","timestamp":1758590009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825003433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":193,"alternative-id":["S1043661825003433"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107918","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107918"}}